الفهرس 
Breast Cancer
The role of GLP-1 and DPP IV enzyme in BCOnly 14 pages are availabe for public view
 |  | from | 279 |  |  |
| | | from | 279 | | |
Abstract
Summary and conclusion Breast cancer is the most frequent malignancy in women worldwide which is curable in 70-80% of cases with early stage and non-metastatic disease. Several risk factors predispose to breast cancer including older age, obesity or high BMI, hormonal factors as early age menarche, late age offirst full term pregnancy, late menopause, hormonal therapy or oral contraceptives and family history. At the molecular level BC is a heterogenous disease which its pathogenesis includes alternation in the genetic and epigenic signaling pathways that affect the cellular activation of human epidermal growth factor
receptor2 (HER2), activation of hormone receptors (estrogen and progesterone) and BRCA mutations. Management of BC is multidisciplinary with different treatment strategies according to molecular subtypes. Chemotherapeutic agents are the most used but their serious cytotoxic effects on various organs limit their use. Also, the tumor chemotherapeutic resistance is considered the major obstacle facing the long-term use of chemotherapeutic agents with subsequent failure and disease progression with bad prognosis. Consequently, modification in cancer treatment strategies has become an urgent necessity Sitagliptin, one of DPP-4 inhibitors which are a class of oral antidiabetic drugs used in the treatment of type II diabetes mellitus. It inhibits the degradation of GIP and GLP-1 that was previously proved to have anti-proliferative and cytotoxic effects toward cancer colon and cytoprotective effects in different organ which have been found to be associated with its antioxidant and anti-inflammatory activities.